Back to top
more

XOMA Royalty Corporation (XOMA)

(Delayed Data from NSDQ)

$30.97 USD

30.97
23,669

+0.77 (2.55%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $30.89 -0.08 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review

by Zacks Equity Research

FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.

    Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up

    by Zacks Equity Research

    Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.

      Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates

      by Zacks Equity Research

      Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.

        Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View

        by Zacks Equity Research

        Zoetis' (ZTS) results exceed both earnings and sales expectations in the fourth quarter of 2017, making it the first animal health company to deliver more than $5 billion in revenues.

          Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y

          by Zacks Equity Research

          Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.

            Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses

            by Zacks Equity Research

            Prothena (PRTA) reported a narrower-than-expected loss in the fourth quarter as the company continued with its pipeline progress.

              Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong

              by Zacks Equity Research

              Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.

                AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda

                by Zacks Equity Research

                AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).

                  Catalyst Gets Positive FDA Advise on Firdapse NDA Refiling

                  by Zacks Equity Research

                  Catalyst (CPRX) posts positive results from a recent Type C meeting with the FDA on resubmitting the new drug application for Firdapse in treating Lambert-Eaton myasthenic syndrome.

                    Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval

                    by Zacks Equity Research

                    Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.

                      ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow

                      by Zacks Equity Research

                      ImmunoGen (IMGN) reports wider-than-expected loss in Q4. However, higher license and milestone fees drive substantial revenue rise year over year.

                        FDA Okays J&J's Prostate Cancer Drug in First-Line Setting

                        by Zacks Equity Research

                        The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.

                          Theravance, J&J Ink Deal for Inflammatory Intestinal Drug

                          by Zacks Equity Research

                          Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.

                            Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4

                            by Zacks Equity Research

                            Alexion (ALXN) surpass earnings and sales estimates in the fourth quarter of 2017. The company received FDA approval for label expansion of Soliris in the United States.

                              Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down

                              by Zacks Equity Research

                              Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.

                                Pfizer Files for Xtandi in Early Stage Prostate Cancer

                                by Zacks Equity Research

                                Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.

                                  Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod

                                  by Zacks Equity Research

                                  The FDA's label expansion approval for Allergan's (AGN) Avycaz marks its third therapeutic indication nod for the anti-infective drug in the United States.

                                    Puma, CANbridge Team Up to Commercialize Nerlynx in China

                                    by Zacks Equity Research

                                    Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.

                                      Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review

                                      by Zacks Equity Research

                                      Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.

                                        Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat

                                        by Zacks Equity Research

                                        Novo Nordisk's (NVO) top-line growth was backed by growth in new-generation insulin, Victoza, Saxenda, and haemophilia products.

                                          Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label

                                          by Zacks Equity Research

                                          Amgen (AMGN) gains consent from the Committee for Medicinal Products for Human Use to add overall survival data from a phase III study on the label of its cancer drug, Kyprolis.

                                            Puma & Medison Team Up to Commercialize Nerlynx in Israel

                                            by Zacks Equity Research

                                            Puma (PBYI) and Medison enters into a licensing deal to commercialize Puma's breast cancer treatment drug Nerlynx in Israel.

                                              Debapriya Chakraborty headshot

                                              Theravance's NDA for COPD Candidate Gets FDA Acceptance

                                              by Debapriya Chakraborty

                                              The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.

                                                Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion

                                                by Zacks Equity Research

                                                The Committee for Medicinal Products for Human Use passes a positive viewpoint on Glaxo's (GSK) shingles vaccine, Shingrix. A final decision from the EU is awaited in April 2018.

                                                  Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y

                                                  by Zacks Equity Research

                                                  Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.